Despite the statutory loss, CSL reported continued underlying profitability, supported by its plasma therapies business and ongoing cost management initiatives. The company said FY2026 represented a period of restructuring and business reset as it focused on improving operational performance and positioning the group for …
Echo IQ Limited (ASX:EIQ) has provided an update on the regulatory status of its EchoSolv HF submission after receiving a Not Substantially Equivalent, or NSE, determination from the United States Food and Drug Administration. The Sydney-based company said it continues to see a clear …
Resonance Health Ltd (ASX:RHT) has reported an improved set of financial results for the year ended 30 June 2026, highlighting a broader shift in the company's underlying performance across its diagnostic technology and clinical trial services businesses. The results mark a return to full-year …
The estimated contract value is approximately A$0.625 million over three years, subject to the actual patient volumes monitored under the platform during that period. On this basis, the company has estimated annual recurring revenue of approximately A$0.21 million over the agreed three-year term, though …
Nanosonics Ltd (ASX:NAN) is an Australian healthcare technology company focused on infection prevention solutions for medical environments. The company’s core technology supports automated disinfection of ultrasound probes, addressing the need for consistent infection control practices across healthcare facilities.
Mesoblast Ltd (ASX:MSB) is a biotechnology company focused on developing cell therapy products for inflammatory diseases, immune disorders and other medical conditions. The company’s FY26 results highlighted commercial progress from Ryoncil, continuedInvestmentin clinical programs and ongoing development of its broader cell therapy pipeline. (Mesoblast)
Neuren Pharmaceuticals Ltd (ASX:NEU) is an Australian biotechnology company focused on developing and commercialising treatments for neurological disorders. The company’s recent focus has shifted towards commercial revenue generation following growth in royalty income from DAYBUE and the introduction of its first dividend program.
PYC Therapeutics Ltd (ASX:PYC) is an Australian biotechnology company focused on developing precision medicines using RNA-based technologies. The company operates within the healthcare sector, where research progress, clinical development and regulatory milestones are important factors influencing biotechnology businesses.
4DMedical Ltd (ASX:4DX) is an Australian medical technology company focused on developing advanced imaging solutions for respiratory health. The company’s technology platform is designed to provide detailed insights into lung function through non-invasive imaging methods.
Ryman Healthcare Ltd (ASX:RYM) is a healthcare and retirement living provider operating integrated retirement villages, aged care facilities and related services. The company’sBusinessmodel combines independent living, assisted care and healthcare services for older residents across New Zealand and Australia.